Furthermore, compared to other Phase III studies, such as IMbrave150, the CheckMate 459 trial did not demonstrate a clear survival advantage, highlighting the limitations of single-agent PD-1 inhibitors in first-line HCC treatment. The gene discussed is PDCD1; the disease is hepatocellular carcinoma.